The Evaluation of Adropin and Autotaxin as Potential Markers of Endothelial Dysfunction in Preeclampsia.

Endothelial dysfunction (ED) plays a prominent role in the pathogenesis of preeclampsia (PE). There is a need for non-invasive methods to assess endothelial function in preeclamptic patients. In the present study, adropin, autotaxin (ATX), and lysophosphatidic acid (LPA) were evaluated as indicators of ED. Patients diagnosed with PE and healthy pregnant women (n = 42 for each group) were compared. After measuring flow-mediated dilation (FMD), the participants were stratified as ED (+) or ED (-) based on a cut-off value of 6.5%. The PE patients were divided as early/late onset PE and severe/mild PE. Adropin, ATX, and LPA levels were measured, and their relevance to ED was evaluated. Student t, Mann-Whitney U, or ANOVA tests were used for statistics, as appropriate. Adropin levels were diminished in the ED (+) group, whereas ATX and LPA levels were increased. The decrease in adropin levels was more pronounced in severe PE, showing a positive correlation with the FMD. In the logistic regression model, adropin was the only parameter that was an independent variable for the FMD test (P < .001). Adropin measurements in serum may be of value for disease follow-up in patients with PE.

[1]  Gustavo Waclawovsky,et al.  Ventilatory Muscle Training for Early Cardiac Rehabilitation Improved Functional Capacity and Modulated Vascular Function of Individuals Undergoing Coronary Artery Bypass Grafting: Pilot Randomized Clinical Trial , 2022, International journal of environmental research and public health.

[2]  D. Martinovic,et al.  Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target , 2021, Biomedicines.

[3]  I. Scott,et al.  ADROPIN: A HEPATOKINE MODULATOR OF VASCULAR FUNCTION AND CARDIAC FUEL METABOLISM. , 2020, American journal of physiology. Heart and circulatory physiology.

[4]  J. Vita,et al.  Nitric Oxide and Endothelial Dysfunction. , 2020, Critical care clinics.

[5]  M. Strowski,et al.  Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research , 2020, Molecules.

[6]  J. Małyszko,et al.  Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. , 2019, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[7]  P. Leeson,et al.  Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring , 2019, Journal of clinical medicine.

[8]  Xuerui Tan,et al.  Negative association between serum adropin and hypertensive disorders complicating pregnancy , 2019, Hypertension in pregnancy.

[9]  G. Lopaschuk,et al.  Adropin Regulates Cardiac Energy Metabolism and Improves Cardiac Function and Efficiency. , 2019, Metabolism: clinical and experimental.

[10]  A. Bhagat,et al.  Serial profile of flow-mediated dilatation in primigravida for prediction of preeclampsia and gestational hypertension , 2018, Hypertension in pregnancy.

[11]  J. Kingdom,et al.  Mechanisms and Clinical Significance of Endothelial Dysfunction in High-Risk Pregnancies. , 2018, The Canadian journal of cardiology.

[12]  W. Gyselaers,et al.  Flow-mediated dilation and peripheral arterial tonometry are disturbed in preeclampsia and reflect different aspects of endothelial function. , 2017, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  Tayfur Çift,et al.  The relationship between maternal and umbilical cord adropin levels with the presence and severity of preeclampsia , 2017, Journal of perinatal medicine.

[14]  H. Erenel,et al.  Maternal serum autotaxin levels in early- and late-onset preeclampsia , 2017, Hypertension in pregnancy.

[15]  V. Muzykantov,et al.  Targeting vascular (endothelial) dysfunction , 2017, British journal of pharmacology.

[16]  M. Dong,et al.  Alteration of serum adropin level in preeclampsia. , 2017, Pregnancy hypertension.

[17]  Y. Osuga,et al.  Placental autotaxin expression is diminished in women with pre‐eclampsia , 2015, The journal of obstetrics and gynaecology research.

[18]  S. Davidge,et al.  Molecular mechanisms of maternal vascular dysfunction in preeclampsia. , 2015, Trends in molecular medicine.

[19]  H. Leite,et al.  Prediction of early and late preeclampsia by flow-mediated dilation of the brachial artery* , 2014, Radiologia brasileira.

[20]  S. Aydin Three new players in energy regulation: Preptin, adropin and irisin , 2014, Peptides.

[21]  Ziwen Zhao,et al.  Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients , 2014, Clinical chemistry and laboratory medicine.

[22]  O. McGuinness,et al.  Adropin Deficiency Is Associated With Increased Adiposity and Insulin Resistance , 2012, Obesity.

[23]  S. Kōzuma,et al.  Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[24]  R. Romero,et al.  The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. , 2011, American journal of obstetrics and gynecology.

[25]  S. Kōzuma,et al.  Expression of autotaxin, an ectoenzyme that produces lysophosphatidic acid, in human placenta. , 2009, American journal of reproductive immunology.

[26]  L. Myatt,et al.  Vascular biology of preeclampsia , 2009, Journal of thrombosis and haemostasis : JTH.

[27]  R. Kesterson,et al.  Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. , 2008, Cell metabolism.

[28]  W. Moolenaar,et al.  Regulation and biological activities of the autotaxin-LPA axis. , 2007, Progress in lipid research.

[29]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[30]  F. Gurdol,et al.  Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome , 2017, Clinical chemistry and laboratory medicine.

[31]  Ryan A. Harris,et al.  Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. , 2011, American journal of physiology. Heart and circulatory physiology.

[32]  pathophysiology and clinical implications , 2022 .